Prediction of genitourinary tract morbidity after brachytherapy for prostate adenocarcinoma

被引:14
|
作者
Wehle, MJ
Lisson, SW
Buskirk, SJ
Broderick, GA
Young, PR
Igel, TC
机构
[1] Mayo Clin, Coll Med, Dept Urol, Jacksonville, FL 32224 USA
[2] Mayo Clin, Coll Med, Dept Radiat Oncol, Jacksonville, FL 32224 USA
关键词
D O I
10.4065/79.3.314
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To investigate whether preoperative genitourinary variables in patients undergoing brachytherapy for localized prostate adenocarcinoma could predict postoperative genitourinary tract morbidity. Patients and Methods: We retrospectively reviewed medical records of 105 men who received either iodine 125. or palladium 103 radioactive seed implants with or without external beam radiotherapy or hormone blockade from January 1, 1998, through December 31, 2000, at the Mayo Clinic in Jacksonville, Fla. Patients with one or more of the following were classified as having a high risk of postoperative genitourinary tract morbidity: American Urological Association symptom scores greater than 15, maximum urinary flow rate less than 10 mL/s, postvoid residual urinary volume greater than 100 mL, or prostate volume greater than 40 cm(3). Of the 105 men, 59 (56%) were classified as high risk and 46 (44%) as low risk. Mean follow-up after brachytherapy was 23.6 months. Modified Radiation Therapy Oncology Group scores were used to assess postoperative genitourinary tract morbidity. The term significant genitourinary tract morbidity was applied to patients with a Radiation Therapy Oncology Group grade of 3 or 4 after at least 6 months of follow-up. Results: Significant morbidity occurred in 37% of high-risk vs 15% of low-risk patients (P=.006). In high-risk patients, transurethral resection or incision of the prostate was required in 5 patients, urethral dilation in 4, direct-vision internal urethrotomy in 1, and placement of a suprapubic catheter in 1. In low-risk patients, transurethral incision of the prostate was required in only 1 patient. Urinary flow rate was a significant individual predictor of postoperative morbidity (P=.03). Conclusions: A combination of urinary flow rate, prostate volume, postvoid residual urinary volume, and American Urological Association symptom score can help identify patients with underlying voiding dysfunction. Urinary flow rate was a statistically significant predictor of genitourinary tract morbidity after brachytherapy for localized prostate adenocarcinoma. Patients and physicians should consider these factors before a patient decides to undergo brachytherapy.
引用
收藏
页码:314 / 317
页数:4
相关论文
共 50 条
  • [31] Influence of multiple genetic polymorphisms on genitourinary morbidity after carbon ion radiotherapy for prostate cancer
    Suga, Tomo
    Iwakawa, Mayumi
    Tsuji, Hiroshi
    Ishikawa, Hitoshi
    Oda, Eisei
    Noda, Shuhei
    Otsuka, Yoshimi
    Ishikawa, Atsuko
    Ishikawa, Ken-Ichi
    Shimazaki, Jun
    Mizoe, Jun-Etsu
    Tsujii, Hirohiko
    Imai, Takashi
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (03): : 808 - 813
  • [32] The impact of acute urinary morbidity on late urinary function after permanent prostate brachytherapy
    Bittner, Nathan
    Merrick, Gregory S.
    Wallner, Kent E.
    Lief, Jonathan H.
    Butler, Wayne M.
    Galbreath, Robert W.
    BRACHYTHERAPY, 2007, 6 (04) : 258 - 266
  • [33] Is long-term urinary morbidity after prostate brachytherapy under-reported?
    Kaul, A.
    Singh, P.
    Smith, G.
    Pigott, K.
    Mishra, V.
    BJU INTERNATIONAL, 2015, 115 : 27 - 27
  • [34] Relationship between the transition zone index of the prostate gland and urinary morbidity after brachytherapy
    Merrick, GS
    Butler, WM
    Galbreath, RW
    Lief, JH
    Donzella, JG
    UROLOGY, 2001, 57 (03) : 524 - 529
  • [35] Regional Quadrant Dosimetry and Late Genitourinary Toxicity After Low-Dose-Rate Prostate Brachytherapy
    Hamilton, S.
    Keyes, M.
    Moravan, V.
    Spadinger, I.
    Morris, W. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E189 - E190
  • [36] Prediction of urinary symptoms after 125iodine prostate brachytherapy
    Kelly, K
    Swindell, R
    Routledge, J
    Burns, M
    Logue, JP
    Wylie, JP
    CLINICAL ONCOLOGY, 2006, 18 (04) : 326 - 332
  • [37] Carcinosarcoma of the Prostate Replacing the Entire Lower Genitourinary Tract
    McGee, Shawn M.
    Boorjian, Stephen A.
    Karnes, R. J.
    UROLOGY, 2009, 74 (03) : 540 - 541
  • [38] Role of ProstaScint® for brachytherapy in localized prostate adenocarcinoma
    Ellis, R
    Kim, E
    Foor, R
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2004, 4 (04) : 435 - 441
  • [39] Temporal resolution of urinary morbidity following prostate brachytherapy
    Merrick, GS
    Butler, WM
    Lief, JH
    Dorsey, AT
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 47 (01): : 121 - 128
  • [40] Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity
    Karlsdottir, Asa
    Muren, Ludvig Paul
    Wentzel-Larsen, Tore
    Dahl, Olav
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 70 (05): : 1478 - 1486